Testing a new drug for non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (BITR2101) that blocks a protein called TNFR2, which may help your immune system fight lymphoma while also slowing tumor growth. It is for people with non-Hodgkin lymphoma, especially cutaneous T-cell lymphoma, who have tried at least 2 other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of non-Hodgkin lymphoma, especially cutaneous T-cell lymphoma (CTCL), that has not responded to treatment or has come back after at least 2 prior therapies.
- Your doctor expects you to live at least 3 more months.
- You are in good enough overall health to be up and about (ECOG performance status 0 or 1).
- You have not taken a PD-1 or PD-L1 immunotherapy in the last 12 months.
- You do not have an active autoimmune disease that required treatment in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.